Xylazine: “Zombie Drug” is an Emerging Threat
ACEP Now
JULY 7, 2023
Since 2020 to 2021, the Drug Enforcement Administration has reported a sharp rise in xylazine use across the U.S., Initial stabilization includes airway management and circulatory support. Currently, there is no FDA-approved pharmacotherapy for either the reversal of xylazine in humans or the management of withdrawal.
98 
Let's personalize your content